Literature DB >> 29933208

Inhibition on angiotensin-converting enzyme exerts beneficial effects on trabecular bone in orchidectomized mice.

Xiang-Fan Chen1, Xiao-Li Li2, Jin-Xin Liu2, Jing Xu3, Yan-Yan Zhao4, Min Yang1, Yan Zhang5.   

Abstract

BACKGROUND: This study aimed to study the osteo-preservative effects of captopril, an inhibitor on angiotensin-converting enzyme (ACE), on bone mass, micro-architecture and histomorphology as well as the modulation of captopril on skeletal renin-angiotensin system (RAS) and regulators for bone metabolism in mice with bilateral orchidectomy.
METHODS: The orchidectomized (ORX) mice were orally administered with vehicle or captopril at low dose (10mg/kg) and high dose (50mg/kg) for six weeks. The distal femoral end, the proximal tibial head and the lumbar vertebra (LV) were stained by hematoxylin and eosin, Safranin O/Fast Green and masson-trichrome. Micro-computed tomography was performed to measure bone mineral density (BMD).
RESULTS: Treatment with captopril increased trabecular bone area at distal metaphysis of femur, proximal metaphysis of tibia and LV-4, moreover, high dose of captopril significantly elevated trabecular BMD of LV-2 and LV-5. The mRNA expressions of renin receptor, angiotensinogen, carbonic anhydrase II, matrix metalloproteinase-9, and tumor necrosis factor-alpha were significantly decreased in tibia of ORX mice following treatment with captopril. The administration with captopril enhanced the ratio of OPG/RANKL mRNA expression, the mRNA expression of transforming growth factor-beta and the protein expression of bradykinin receptor-1.
CONCLUSIONS: The inhibition on ACE by captopril exerts beneficial effects on trabecular bone of ORX mice. The therapeutic efficacy may be attributed to the regulation of captopril on local RAS and cytokines in bone.
Copyright © 2018 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Angiotensin-converting enzyme; Captopril; Orchidectomized; Renin-angiotensin system; Trabecular bone

Mesh:

Substances:

Year:  2018        PMID: 29933208      PMCID: PMC7102314          DOI: 10.1016/j.pharep.2018.02.008

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  42 in total

Review 1.  Male osteoporosis: new trends in diagnosis and therapy.

Authors:  Hosam K Kamel
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 2.  Antihypertensive medications, bone mineral density, and fractures: a review of old cardiac drugs that provides new insights into osteoporosis.

Authors:  Mahua Ghosh; Sumit R Majumdar
Journal:  Endocrine       Date:  2014-02-07       Impact factor: 3.633

Review 3.  Targeting inflammation: new therapeutic approaches in chronic kidney disease (CKD).

Authors:  Daniela Impellizzeri; Emanuela Esposito; James Attley; Salvatore Cuzzocrea
Journal:  Pharmacol Res       Date:  2014-03-03       Impact factor: 7.658

4.  ACE Phenotyping as a Guide Toward Personalized Therapy With ACE Inhibitors.

Authors:  Sergei M Danilov; Stan I Tovsky; David E Schwartz; Randal O Dull
Journal:  J Cardiovasc Pharmacol Ther       Date:  2017-01-10       Impact factor: 2.457

Review 5.  Rationale for combining a direct renin inhibitor with other renin- angiotensin system blockers. Focus on aliskiren and combinations.

Authors:  Helmy M Siragy
Journal:  Cardiovasc Drugs Ther       Date:  2011-02       Impact factor: 3.727

6.  Involvement of the skeletal renin-angiotensin system in age-related osteoporosis of ageing mice.

Authors:  Sa-sa Gu; Yan Zhang; Xiao-li Li; Shu-yan Wu; Teng-yue Diao; Rong Hai; Hong-Wen Deng
Journal:  Biosci Biotechnol Biochem       Date:  2012-07-07       Impact factor: 2.043

7.  [Evolution of the bone mass of hypertense menopausal women in treatment with fosinopril].

Authors:  Alicia García-Testal; Ana Monzó; Gloria Rabanaque; Antonio González; Alberto Romeu
Journal:  Med Clin (Barc)       Date:  2006-11-11       Impact factor: 1.725

8.  Bradykinin regulates osteoblast differentiation by Akt/ERK/NFκB signaling axis.

Authors:  Swati Srivastava; Kirti Sharma; Narender Kumar; Partha Roy
Journal:  J Cell Physiol       Date:  2014-12       Impact factor: 6.384

9.  Early molecular responses of bone to obstructive nephropathy induced by unilateral ureteral obstruction in mice.

Authors:  Sa-Sa Gu; Yan Zhang; Shu-Yan Wu; Teng-Yue Diao; Yoseph Asmelash Gebru; Hong-Wen Deng
Journal:  Nephrology (Carlton)       Date:  2012-11       Impact factor: 2.506

10.  Effect of Angiotensin-converting Enzyme Inhibitor on Cardiac Fibrosis and Oxidative Stress Status in Lipopolysaccharide-induced Inflammation Model in Rats.

Authors:  Azam Abareshi; Fatemeh Norouzi; Fereshteh Asgharzadeh; Farimah Beheshti; Mahmoud Hosseini; Mehdi Farzadnia; Majid Khazaei
Journal:  Int J Prev Med       Date:  2017-09-06
View more
  3 in total

1.  Osteoprotective action of low-salt diet requires myeloid cell-derived NFAT5.

Authors:  Agnes Schröder; Patrick Neubert; Jens Titze; Aline Bozec; Wolfgang Neuhofer; Peter Proff; Christian Kirschneck; Jonathan Jantsch
Journal:  JCI Insight       Date:  2019-12-05

2.  Anti-Inflammatory Activities of Captopril and Diuretics on Macrophage Activity in Mouse Humoral Immune Response.

Authors:  Paweł Bryniarski; Katarzyna Nazimek; Janusz Marcinkiewicz
Journal:  Int J Mol Sci       Date:  2021-10-21       Impact factor: 5.923

3.  Salt-Sensitive Hypertension Induces Osteoclastogenesis and Bone Resorption via Upregulation of Angiotensin II Type 1 Receptor Expression in Osteoblasts.

Authors:  Adya Pramusita; Hideki Kitaura; Fumitoshi Ohori; Takahiro Noguchi; Aseel Marahleh; Yasuhiko Nara; Ria Kinjo; Jinghan Ma; Kayoko Kanou; Yukinori Tanaka; Itaru Mizoguchi
Journal:  Front Cell Dev Biol       Date:  2022-04-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.